首页> 外文期刊>ACS applied materials & interfaces >Cell Microenvironment-Controlled Antitumor Drug Releasing-Nanomicelles for GLUT1-Targeting Hepatocellular Carcinoma Therapy
【24h】

Cell Microenvironment-Controlled Antitumor Drug Releasing-Nanomicelles for GLUT1-Targeting Hepatocellular Carcinoma Therapy

机译:细胞微环境控制的抗肿瘤药物释放基因枪,用于靶向GLUT1的肝细胞癌治疗。

获取原文
获取原文并翻译 | 示例
       

摘要

In clinical therapy, the poor prognosis of hepatocellular carcinoma (HCC) is mainly attributed to the failure of chemotherapeutical agents to accumulate in tumor as well as their serious systemic toxicity. In this work, we developed actively tumor-targeting trilayer micelles with microenvironment-sensitive cross-links as a novel nanocarrier for HCC therapy. These micelles comprised biodegradable PEG-pLys-pPhe polymers, in which pLys could react with a disulfide-containing agent to form redox-responsive cross-links. In vitro drug release and pharmacokinetics studies showed that these cross-links were stable in physiological condition whereas cleaved once internalized into cells due to the high level of glutathione, resulting in facilitated intracellular doxorubicin release. In addition, dehydroascorbic acid (DHAA) was decorated on the surface of micelles for specific recognition of tumor cells via GLUT1, a member of glucose transporter family overexpressed on hepatocarcinoma cells. Moreover, DHAA exhibited a "one-way" continuous accumulation within tumor cells. Cellular uptake and in vivo imaging studies proved that these micelles had remarkable targeting property toward hepatocarcinoma cells and tumor. Enhanced anti-HCC efficacy of the micelles was also confirmed both in vitro and in vivo. Therefore, this micellar system may be a potential platform of chemotherapeutics delivery for HCC therapy.
机译:在临床治疗中,肝细胞癌(HCC)的预后不良主要归因于化学治疗剂在肿瘤中蓄积的失败及其严重的全身毒性。在这项工作中,我们开发了具有微环境敏感性交联的主动靶向肿瘤的三层胶束,作为用于HCC治疗的新型纳米载体。这些胶束包含可生物降解的PEG-pLys-pPhe聚合物,其中pLys可以与含二硫键的试剂反应形成氧化还原响应性交联。体外药物释放和药代动力学研究表明,这些交联在生理条件下是稳定的,而由于谷胱甘肽的含量高,一旦被内化进入细胞就被切割,从而促进了细胞内阿霉素的释放。此外,在胶束表面修饰了脱氢抗坏血酸(DHAA),以通过GLUT1(在肝癌细胞上过表达的葡萄糖转运蛋白家族的成员)特异性识别肿瘤细胞。此外,DHAA在肿瘤细胞内表现出“单向”连续积累。细胞摄取和体内成像研究证明,这些胶束对肝癌细胞和肿瘤具有显着的靶向特性。在体外和体内也都证实了胶束的增强的抗HCC功效。因此,该胶束系统可能是用于HCC治疗的化学治疗的潜在平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号